Hours

Minutes

Seconds

-40%

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Last Transcript: Vivesto AB

Vivesto AB - Special Call

11-24

More transcripts

Analysts' recommendations: Vivesto AB

05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
11-21	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
13/08/25	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
09/07/24	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
30/12/22	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

More recommendations

News in other languages: Vivesto AB

25/03/20	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
30/01/20	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

More news

Managers and Directors: Vivesto AB

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	22/01/2023
Robert Maiorana DFI	Director of Finance/CFO	66	30/06/2022
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	31/12/2022

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	24/05/2022
Hege Hellstrom BRD	Director/Board Member	61	25/09/2019
Pål Ryfors BRD	Director/Board Member	43	24/05/2022

More insiders

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Cap	98.42M 10.25M 8.95M 8.28M 7.73M 14.51M 968M 14.62M 38.3M 476M 38.47M 37.64M 1.65B	P/E 2026 *	-2.91x	P/E 2027 *	-2.12x
Enterprise Value	90.42M 9.41M 8.23M 7.61M 7.1M 13.33M 890M 13.43M 35.18M 437M 35.35M 34.58M 1.52B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	56.4%	Yield 2026 *	-	Yield 2027 *	-

06-16	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study	CI
06-16	Vivesto reports positive results for intravenous Cantrixil	FW
06-05	Sweden's Vivesto Names New Finance Chief	MT
06-05	Vivesto appoints Björn Svanström as new CFO	FW
06-04	Vivesto AB Announces Chief Financial Officer Changes	CI
05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
05-20	Vivesto trades on Nasdaq Stockholm today following 1:100 reverse stock split	FW
05-20	Calendar Wednesday May 20	FW
05-13	Vivesto sets record date for reverse share split as May 21, 2026	RE
05-13	Vivesto sets timetable for reverse stock split	FW
05-07	Vivesto Q1 operating result of SEK -6.8 mln	RE
05-07	Vivesto reports narrowed operating loss	FW
04-01	Sweden's Vivesto Plans Reverse Share Split, Share Capital Reduction	MT

06-16	Vivesto: Positive data for Cantrixil	AQ
06-16	Vivesto reports positive results from i.v. Cantrixil PK/toxicology study	AQ
06-05	Vivesto appoints Björn Svanström as CFO	AQ
05-29	New number of shares and votes in Vivesto	AQ
05-26	Vivesto: Minor model adjustments	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVESTO AB	-.--%	-99.00%	-	-	10.25M
ELI LILLY AND COMPANY	+0.32%	-2.41%	+44.49%	+140.80%	983B
JOHNSON & JOHNSON	+1.27%	-1.85%	+54.41%	+39.65%	557B
ABBVIE INC.	+6.25%	+3.80%	+24.13%	+67.39%	406B
ROCHE HOLDING AG	+0.25%	-1.93%	+23.33%	+16.35%	314B
ASTRAZENECA PLC	+0.42%	+0.68%	+27.89%	+14.57%	273B
NOVARTIS AG	+1.67%	+0.05%	+26.76%	+33.56%	272B
NOVO NORDISK A/S	+2.39%	+5.02%	-36.96%	-44.76%	203B
AMGEN INC.	+2.11%	-1.66%	+19.14%	+50.10%	186B
GILEAD SCIENCES, INC.	+0.90%	+0.46%	+15.09%	+59.86%	155B
Average	+1.56%	-0.92%	+22.03%	+41.95%	372.26B
Weighted average by Cap.	+1.56%	-2.22%	+31.18%	+64.35%

	2026 *	2027 *
Net sales	-	-
Net income	-31M -3.23M -2.82M -2.61M -2.43M -4.57M -305M -4.6M -12.06M -150M -12.12M -11.86M -521M	-46M -4.79M -4.18M -3.87M -3.61M -6.78M -453M -6.83M -17.9M -223M -17.98M -17.59M -773M
Net Debt	-8M -833K -728K -673K -628K -1.18M -78.71M -1.19M -3.11M -38.7M -3.13M -3.06M -134M	-10M -1.04M -910K -842K -785K -1.47M -98.39M -1.49M -3.89M -48.37M -3.91M -3.82M -168M

Vivesto AB Share Price OTC Markets

Stocks

OASMY

US67421W1099

Pharmaceuticals

Valuation: Vivesto AB

Chart: Vivesto AB

Latest news : Vivesto AB

Last Transcript: Vivesto AB

Analysts' recommendations: Vivesto AB

Press Releases: Vivesto AB

News in other languages: Vivesto AB

Managers and Directors: Vivesto AB

Other Pharmaceuticals

Financials

Company Profile